• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于识别病原体中耐药突变和适应特征的综合蛋白质设计方案。

A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens.

作者信息

Padhi Aditya K, Tripathi Timir

出版信息

Brief Funct Genomics. 2023 Apr 13;22(2):195-203. doi: 10.1093/bfgp/elac020.

DOI:10.1093/bfgp/elac020
PMID:35851634
Abstract

Most pathogens mutate and evolve over time to escape immune and drug pressure. To achieve this, they alter specific hotspot residues in their intracellular proteins to render the targeted drug(s) ineffective and develop resistance. Such hotspot residues may be located as a cluster or uniformly as a signature of adaptation in a protein. Identifying the hotspots and signatures is extremely important to comprehensively understand the disease pathogenesis and rapidly develop next-generation therapeutics. As experimental methods are time-consuming and often cumbersome, there is a need to develop efficient computational protocols and adequately utilize them. To address this issue, we present a unique computational protein design protocol that identifies hotspot residues, resistance mutations and signatures of adaptation in a pathogen's protein against a bound drug. Using the protocol, the binding affinity between the designed mutants and drug is computed quickly, which offers predictions for comparison with biophysical experiments. The applicability and accuracy of the protocol are shown using case studies of a few protein-drug complexes. As a validation, resistance mutations in severe acute respiratory syndrome coronavirus 2 main protease (Mpro) against narlaprevir (an inhibitor of hepatitis C NS3/4A serine protease) are identified. Notably, a detailed methodology and description of the working principles of the protocol are presented. In conclusion, our protocol will assist in providing a first-hand explanation of adaptation, hotspot-residue variations and surveillance of evolving resistance mutations in a pathogenic protein.

摘要

大多数病原体随着时间的推移会发生突变和进化,以逃避免疫和药物压力。为实现这一目的,它们会改变细胞内蛋白质中的特定热点残基,使靶向药物失效并产生耐药性。此类热点残基可能成簇分布,也可能均匀分布,作为蛋白质适应性的一种特征。识别这些热点和特征对于全面了解疾病发病机制以及快速开发下一代治疗方法极为重要。由于实验方法耗时且往往繁琐,因此需要开发高效的计算方案并充分加以利用。为解决这一问题,我们提出了一种独特的计算蛋白质设计方案,该方案可识别病原体蛋白质中针对结合药物的热点残基、耐药突变和适应性特征。使用该方案,可以快速计算设计的突变体与药物之间的结合亲和力,从而为与生物物理实验进行比较提供预测。通过对一些蛋白质-药物复合物的案例研究展示了该方案的适用性和准确性。作为验证,我们识别了严重急性呼吸综合征冠状病毒2主要蛋白酶(Mpro)对那洛普韦(一种丙型肝炎NS3/4A丝氨酸蛋白酶抑制剂)的耐药突变。值得注意的是,本文还介绍了该方案的详细方法和工作原理说明。总之,我们的方案将有助于对致病蛋白质中的适应性、热点残基变异以及不断演变的耐药突变监测提供第一手解释。

相似文献

1
A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens.一种用于识别病原体中耐药突变和适应特征的综合蛋白质设计方案。
Brief Funct Genomics. 2023 Apr 13;22(2):195-203. doi: 10.1093/bfgp/elac020.
2
Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.靶向设计 SARS-CoV-2 主蛋白酶的药物结合位点揭示了潜在的适应性特征。
Biochem Biophys Res Commun. 2021 May 28;555:147-153. doi: 10.1016/j.bbrc.2021.03.118. Epub 2021 Mar 26.
3
Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.基于分子动力学模拟、残基相互作用网络和底物包络分析联用的对 HCV NS3/4A 蛋白酶抑制剂瓦尼普韦和 MK-5172 的耐药机制的计算研究。
J Chem Inf Model. 2014 Feb 24;54(2):621-33. doi: 10.1021/ci400060j. Epub 2013 Jun 28.
4
Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.丙型肝炎病毒NS3/4A蛋白酶V36M、R155K、V36M+R155K、T54A和A156T突变导致那拉普瑞韦耐药性分子机制的计算研究
Biochem Cell Biol. 2014 Oct;92(5):357-69. doi: 10.1139/bcb-2014-0039. Epub 2014 Jul 23.
5
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.针对丙型肝炎病毒 NS3/4A 蛋白酶抑制剂的耐药性的分子基础。
PLoS Pathog. 2012;8(7):e1002832. doi: 10.1371/journal.ppat.1002832. Epub 2012 Jul 26.
6
Genetic Surveillance of SARS-CoV-2 M Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.SARS-CoV-2 M 基因监测显示,在引入蛋白酶抑制剂帕克洛维德之前,其序列和结构高度保守。
mBio. 2022 Aug 30;13(4):e0086922. doi: 10.1128/mbio.00869-22. Epub 2022 Jul 13.
7
Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.丙型肝炎NS3/4A蛋白酶突变导致博赛泼维耐药背后的分子机制
Gene. 2015 Oct 1;570(1):115-21. doi: 10.1016/j.gene.2015.06.008. Epub 2015 Jun 6.
8
Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.针对 HCV NS3/4A 丝氨酸蛋白酶突变体 R155K、A156V 和 D168A 对 TMC435 的耐药机制的分子建模研究。
Antiviral Res. 2012 Jan;93(1):126-37. doi: 10.1016/j.antiviral.2011.11.007. Epub 2011 Nov 22.
9
Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.asunaprevir对丙型肝炎病毒NS3/4A蛋白酶中R155K和D168A点突变的低敏感性:分子动力学模拟
J Mol Graph Model. 2019 Jun;89:122-130. doi: 10.1016/j.jmgm.2019.03.006. Epub 2019 Mar 11.
10
Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.理解与全长NS3/4A结合的抑制剂和底物的结构与能量基础:来自分子动力学模拟、结合自由能计算和网络分析的见解
Mol Biosyst. 2012 Oct;8(10):2753-65. doi: 10.1039/c2mb25157d.

引用本文的文献

1
Computational Protein Design for COVID-19 Research and Emerging Therapeutics.用于新冠病毒研究和新兴疗法的计算蛋白质设计
ACS Cent Sci. 2023 Mar 20;9(4):602-613. doi: 10.1021/acscentsci.2c01513. eCollection 2023 Apr 26.
2
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.SARS-CoV-2 主蛋白酶结合位点的热点残基和耐药突变:设计、鉴定及与全球流行病毒基因组的相关性。
Biochem Biophys Res Commun. 2022 Nov 12;629:54-60. doi: 10.1016/j.bbrc.2022.09.010. Epub 2022 Sep 7.